Bubendorf/Basel, Switzerland, October 4, 2016 – Bachem Group (SIX: BANB) and DOTTIKON ES announce that they are extending their collaboration in the area of novel amino acids. The collaboration between the two Swiss companies covers the development, manufacturing, and distribution of innovative, enantiomerically pure amino acids, for example for peptide synthesis. Dr. José de Chastonay, Chief Marketing Officer of Bachem Holding AG, has the following to say about the partnership: “We are pleased to collaborate with DOTTIKON ES to bring innovative, new amino acid derivatives for peptide synthesis to our worldwide customer base. Due to the special chemical skills of DOTTIKON ES, special, enantiomerically pure amino acid derivatives of high quality can be manufactured very efficiently.” Bachem is the global leader in exclusive custom synthesis of peptides for preclinical and clinical pharmaceutical research. DOTTIKON ES, the specialist for hazardous reactions, provides innovative technology for the stereoselective synthesis of chiral building blocks as well as longstanding experience in chemical process development, scale-up and production.